Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
In the latest session, Cardiff Oncology Inc (NASDAQ: CRDF) closed at $2.81 down -2.09% from its previous closing price of $2.87. In other words, the price has decreased by -$2.09 from its previous closing price. On the day, 0.57 million shares were traded. CRDF stock price reached its highest trading level at $2.87 during the session, while it also had its lowest trading level at $2.75.
Ratios:
For a deeper understanding of Cardiff Oncology Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.20 and its Current Ratio is at 4.20. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In the most recent recommendation for this company, Noble Capital Markets on January 05, 2026, initiated with a Outperform rating and assigned the stock a target price of $12.
On July 08, 2025, Ladenburg Thalmann started tracking the stock assigning a Buy rating and target price of $19.
On June 24, 2025, Jefferies started tracking the stock assigning a Hold rating and target price of $3.50.Jefferies initiated its Hold rating on June 24, 2025, with a $3.50 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Jul 30 ’25 when PACE GARY W bought 275,000 shares for $2.45 per share. The transaction valued at 673,750 led to the insider holds 1,330,676 shares of the business.
PACE GARY W bought 15,000 shares of CRDF for $36,750 on Jul 30 ’25. The Director now owns 1,345,676 shares after completing the transaction at $2.45 per share.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CRDF now has a Market Capitalization of 189283168 and an Enterprise Value of 129702184. For the stock, the TTM Price-to-Sale (P/S) ratio is 378.56 while its Price-to-Book (P/B) ratio in mrq is 3.86. Its current Enterprise Value per Revenue stands at 258.887 whereas that against EBITDA is -2.432.
Stock Price History:
The Beta on a monthly basis for CRDF is 1.33, which has changed by -0.15588236 over the last 52 weeks, in comparison to a change of 0.17287207 over the same period for the S&P500. Over the past 52 weeks, CRDF has reached a high of $4.99, while it has fallen to a 52-week low of $1.90. The 50-Day Moving Average of the stock is 13.85%, while the 200-Day Moving Average is calculated to be 3.27%.
Shares Statistics:
For the past three months, CRDF has traded an average of 907.34K shares per day and 962680 over the past ten days. A total of 67.09M shares are outstanding, with a floating share count of 61.36M. Insiders hold about 8.91% of the company’s shares, while institutions hold 31.18% stake in the company. Shares short for CRDF as of 1767139200 were 15654534 with a Short Ratio of 17.25, compared to 1764288000 on 15589278. Therefore, it implies a Short% of Shares Outstanding of 15654534 and a Short% of Float of 23.849999999999998.
Earnings Estimates
. The current market rating for Cardiff Oncology Inc (CRDF) reflects the collective analysis of 6.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is -$0.19, with high estimates of -$0.16 and low estimates of -$0.21.
Analysts are recommending an EPS of between -$0.76 and -$0.84 for the fiscal current year, implying an average EPS of -$0.78. EPS for the following year is -$0.76, with 6.0 analysts recommending between -$0.55 and -$0.97.
Revenue Estimates
A total of 9 analysts have provided revenue estimates for CRDF’s current fiscal year. The highest revenue estimate was $500k, while the lowest revenue estimate was $300k, resulting in an average revenue estimate of $455.56k. In the same quarter a year ago, actual revenue was $683k
